Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.74 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 5/20 | 0.45 |
| ▸ | DUT | P33316 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 2/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | SCN1A | P35498 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31686185 | 1.00 | CYP3A4 (0.74) | CYP3A4CYP2B6HTTSMN1; SMN2PGR | |
| SCHEMBL16321750 | 1.00 | CYP3A4 (0.74) | CYP3A4CYP2B6HTTSMN1; SMN2PGR | |
| SCHEMBL16320678 | 0.87 | CYP3A4 (0.69) | CYP3A4CYP2B6HTTSMN1; SMN2PGR | |
| SCHEMBL16320677 | 0.87 | CYP3A4 (0.69) | CYP3A4CYP2B6HTTSMN1; SMN2PGR | |
| SCHEMBL16324389 | 0.86 | CYP3A4 (0.76) | CYP3A4CYP2B6HTTSMN1; SMN2PGR | |
| SCHEMBL16320866 | 0.86 | CYP3A4 (0.76) | CYP3A4CYP2B6HTTSMN1; SMN2PGR | |
| SCHEMBL16324388 | 0.86 | CYP3A4 (0.76) | CYP3A4CYP2B6HTTSMN1; SMN2PGR | |
| SCHEMBL16320868 | 0.86 | CYP3A4 (0.76) | CYP3A4CYP2B6HTTSMN1; SMN2PGR | |
| SCHEMBL16320887 | 0.86 | CYP3A4 (0.76) | CYP3A4CYP2B6HTTSMN1; SMN2PGR | |
| SCHEMBL16320885 | 0.86 | CYP3A4 (0.76) | CYP3A4CYP2B6HTTSMN1; SMN2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744664-A2 | PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS | MyoKardia, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12616697-B2 | Methods of treatment with myosin modulator | MyoKardia, Inc. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20240382486-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2024-11-21 | — | — | US | disclosed |
| US-20240299390-A1 | Methods of Treatment with Myosin Modulator | MyoKardia, Inc. | 2024-09-12 | — | — | US | disclosed |
| US-RE50050-E1 | Pyrimidinedione compounds | MyoKardia, Inc. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240115568-A1 | Methods of Administering Myosin Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2024-04-11 | — | — | US | disclosed |
| WO-2023211872-A1 | METHODS OF ADMINISTERING MYOSIN INHIBITORS | MyoKardia, Inc. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20230338378-A1 | Methods of Administering Myosin Inhibitors | MyoKardia, Inc. | 2023-10-26 | — | — | US | disclosed |
| EP-4203927-A1 | METHODS OF TREATMENT WITH MYOSIN MODULATOR | MyoKardia, Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20230165860-A1 | PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2023-06-01 | — | — | US | disclosed |
| EP-3702352-A1 | PYRIMIDINEDIONE COMPOUND AGAINST CARDIAC CONDITIONS | Myokardia, Inc. (US) | 2020-09-02 | — | — | EP | disclosed |
| EP-3010910-B1 | PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS | MYOKARDIA INC (US) | 2020-02-05 | — | — | EP | disclosed |
| US-20180311242-A1 | PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2018-11-01 | — | — | US | disclosed |
| US-20170281626-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2017-10-05 | — | — | US | disclosed |
| US-9585883-B2 | Pyrimidinedione compounds | MyoKardia, Inc. (US) | 2017-03-07 | — | — | US | disclosed |
| EP-3010910-A1 | PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS | Myokardia, Inc. (US) | 2016-04-27 | — | — | EP | disclosed |
| US-20160030428-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2016-02-04 | — | — | US | disclosed |
| US-9181200-B2 | Pyrimidinedione compounds | MyoKardia, Inc. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140378464-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2014-12-25 | — | — | US | disclosed |
| WO-2014205223-A1 | PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS | MyoKardia, Inc. (US) | 2014-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378464-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | CYP3A4 2600/4885CYP2B6 1992/4885HTT 286/4885 |
| US-20240299390-A1 | Methods of Treatment with Myosin Modulator | MYH10, MYH2, MYO3A | CYP3A4 4745/4885CYP2B6 4760/4885HTT 3078/4885 |
| US-20240382486-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | CYP3A4 2600/4885CYP2B6 1992/4885HTT 286/4885 |
| US-20160030428-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | CYP3A4 2600/4885CYP2B6 1992/4885HTT 286/4885 |
| US-12616697-B2 | Methods of treatment with myosin modulator | MYH2, MYH14, MYH10 | CYP3A4 3296/4885CYP2B6 4375/4885HTT 526/4885 |
| US-20170281626-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | CYP3A4 2600/4885CYP2B6 1992/4885HTT 286/4885 |
| US-20230338378-A1 | Methods of Administering Myosin Inhibitors | MYH2, MYLK2, MYH10 | CYP3A4 3078/4885CYP2B6 3439/4885HTT 1999/4885 |
| US-20230165860-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | CYP3A4 2600/4885CYP2B6 1992/4885HTT 286/4885 |
| US-20180311242-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | CYP3A4 2600/4885CYP2B6 1992/4885HTT 286/4885 |
| US-20240115568-A1 | Methods of Administering Myosin Inhibitors | MYH2, MYLK2, MYH10 | CYP3A4 3078/4885CYP2B6 3439/4885HTT 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.